Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 3/20 | 0.32 |
| ▸ | F10 | P00742 | 7/20 | 0.32 |
| ▸ | F2 | P00734 | 4/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093467 | 1.00 | MAPK14 (0.35) | MAPK14LCKCSF1RF11F10 | |
| SCHEMBL1092472 | 0.85 | MAPK14 (0.31) | MAPK14LCKCSF1R | |
| SCHEMBL1092474 | 0.85 | MAPK14 (0.31) | MAPK14LCKCSF1R | |
| SCHEMBL1104458 | 0.79 | ROCK2 (0.36) | MAPK14 | |
| SCHEMBL1104462 | 0.78 | — | — | |
| SCHEMBL4190944 | 0.77 | MAPK14 (0.33) | MAPK14LCKCSF1RF11F7 | |
| SCHEMBL1093761 | 0.76 | TRPV1 (0.38) | — | |
| SCHEMBL1093759 | 0.76 | TRPV1 (0.38) | — | |
| SCHEMBL1093173 | 0.75 | PTGS2 (0.35) | — | |
| SCHEMBL1093171 | 0.75 | PTGS2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153807-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2021336-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090111809-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BUSH JULIE KAY | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111809-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | MAPK14 1073/4885LCK 3247/4885CSF1R 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.